A high-fat, high-sugar diet may affect the effectiveness of breast cancer treatment

is well known that high-fat, high-sugar foods are harmful and even increase the risk of cancer. Now, a new U.S. study has found that high-fat, high-sugar foods lead to elevated levels of glycosylated end-product (AGEs) in the body, affecting the effectiveness of treatment for some breast cancer patients.
the accumulation of glycosylated end products in the body is the result of the breakdown of nutrients, sugars and fats, which is an unavoidable natural process. It has previously been found that glyco-based end-product aggregation may be associated with a range of diseases, including diabetes, Alzheimer's disease, cardiovascular disease, etc.
researchers at the University of South Carolina medical school found that processed foods rich in fat and sugar, or cooked through grilling, frying, frying, etc., increased levels of glycosylated end-products in the body. For estrogen-positive breast cancer patients, elevated levels of end-of-glycosylation in the body can affect the therapeutic effect of tymoxifen. Thoxyfen is an estrogen-like regulator and is a common treatment for this type of breast cancer.
using the breast cancer cell line model showed that the end product of glycosylation increased phosphate of the estrogen-like alpha, thereby continuously activating a path path and promoting the growth of breast cancer cells. Adding tymoxifen will inhibit the growth of these cancer cells, but adding glycosylation to the end product will cause the cancer cells to grow again. This means that in patients with estrogen-positive breast cancer patients with high levels of glyco-based end products, the treatment of tymoxifen may not be very effective.
paper has been published in the academic journal Breast Cancer Research and Treatment. David Turner, an assistant professor at the University of South Carolina Medical University who led the study, said the study sheds light on the effects of diet-related end-of-glycosylation products on the effectiveness of breast cancer therapy, which may be able to design lifestyle interventions to minimize elevated levels of end-of-life glycosylation in patients. (Source: Xinhua News Agency)